Az angiogén utak gátlása bevacizumabbal az emlocombining double acute accentrák kezelésében

Translated title of the contribution: Anti-VEGF therapy with bevacizumab in breast cancer

J. Tóth, Gonda Andrea, J. Szántó

Research output: Contribution to journalArticle

Abstract

The growth of new blood vessels, angiogenesis is important for tumour progression and metastasis. Vascular endothelial growth factor (VEGF) plays multiple roles in cancer development. Due to it the VEGF seems to be an optimal therapeutic target in breast cancer therapy. The plasma level of this growth factor is highest early in disease suggests that anti-VEGF agents may provide their greatest benefit in firts-line chemotherapy with metastatic breast cancer (MBC). A phase III trial, E2100 evaluated weekly paclitaxel with or without bevacizumab (Avastin), the specific humanised anti-VEGF monoclonal antibody in patients with previously untreated locally recurrent or MBC, doubling of progression-free survival for all patient subgroups. Bevacizumab is generally well tolerated. The most common adverse events observed in trials hypertension, proteinuria, and wound-healing complications, most of which are grade 1-2 in severity. The registration of bevacizumab for MBC therapy brings new hope for patients. Novel approach of bevacizumab for MBC would be combination chemotherapy and different targeted therapies. Phase III clinical trials of bevacizumab are ongoing in different stages in different settings.

Original languageHungarian
Pages (from-to)669-673
Number of pages5
JournalLege Artis Medicinae
Volume18
Issue number10
Publication statusPublished - Oct 2008

Fingerprint

Vascular Endothelial Growth Factor A
Breast Neoplasms
Therapeutics
Phase III Clinical Trials
Paclitaxel
Combination Drug Therapy
Proteinuria
Wound Healing
Disease-Free Survival
Blood Vessels
Bevacizumab
Neoplasms
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Neoplasm Metastasis
Hypertension
Drug Therapy
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az angiogén utak gátlása bevacizumabbal az emlocombining double acute accentrák kezelésében. / Tóth, J.; Andrea, Gonda; Szántó, J.

In: Lege Artis Medicinae, Vol. 18, No. 10, 10.2008, p. 669-673.

Research output: Contribution to journalArticle

@article{d81c0191fe1b41ba8ac5e53c5c80a474,
title = "Az angiog{\'e}n utak g{\'a}tl{\'a}sa bevacizumabbal az emlocombining double acute accentr{\'a}k kezel{\'e}s{\'e}ben",
abstract = "The growth of new blood vessels, angiogenesis is important for tumour progression and metastasis. Vascular endothelial growth factor (VEGF) plays multiple roles in cancer development. Due to it the VEGF seems to be an optimal therapeutic target in breast cancer therapy. The plasma level of this growth factor is highest early in disease suggests that anti-VEGF agents may provide their greatest benefit in firts-line chemotherapy with metastatic breast cancer (MBC). A phase III trial, E2100 evaluated weekly paclitaxel with or without bevacizumab (Avastin), the specific humanised anti-VEGF monoclonal antibody in patients with previously untreated locally recurrent or MBC, doubling of progression-free survival for all patient subgroups. Bevacizumab is generally well tolerated. The most common adverse events observed in trials hypertension, proteinuria, and wound-healing complications, most of which are grade 1-2 in severity. The registration of bevacizumab for MBC therapy brings new hope for patients. Novel approach of bevacizumab for MBC would be combination chemotherapy and different targeted therapies. Phase III clinical trials of bevacizumab are ongoing in different stages in different settings.",
keywords = "Bevacizumab, Metastatic breast cancer (MBC), Vascular endothelial growth factor (VEGF)",
author = "J. T{\'o}th and Gonda Andrea and J. Sz{\'a}nt{\'o}",
year = "2008",
month = "10",
language = "Hungarian",
volume = "18",
pages = "669--673",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - Az angiogén utak gátlása bevacizumabbal az emlocombining double acute accentrák kezelésében

AU - Tóth, J.

AU - Andrea, Gonda

AU - Szántó, J.

PY - 2008/10

Y1 - 2008/10

N2 - The growth of new blood vessels, angiogenesis is important for tumour progression and metastasis. Vascular endothelial growth factor (VEGF) plays multiple roles in cancer development. Due to it the VEGF seems to be an optimal therapeutic target in breast cancer therapy. The plasma level of this growth factor is highest early in disease suggests that anti-VEGF agents may provide their greatest benefit in firts-line chemotherapy with metastatic breast cancer (MBC). A phase III trial, E2100 evaluated weekly paclitaxel with or without bevacizumab (Avastin), the specific humanised anti-VEGF monoclonal antibody in patients with previously untreated locally recurrent or MBC, doubling of progression-free survival for all patient subgroups. Bevacizumab is generally well tolerated. The most common adverse events observed in trials hypertension, proteinuria, and wound-healing complications, most of which are grade 1-2 in severity. The registration of bevacizumab for MBC therapy brings new hope for patients. Novel approach of bevacizumab for MBC would be combination chemotherapy and different targeted therapies. Phase III clinical trials of bevacizumab are ongoing in different stages in different settings.

AB - The growth of new blood vessels, angiogenesis is important for tumour progression and metastasis. Vascular endothelial growth factor (VEGF) plays multiple roles in cancer development. Due to it the VEGF seems to be an optimal therapeutic target in breast cancer therapy. The plasma level of this growth factor is highest early in disease suggests that anti-VEGF agents may provide their greatest benefit in firts-line chemotherapy with metastatic breast cancer (MBC). A phase III trial, E2100 evaluated weekly paclitaxel with or without bevacizumab (Avastin), the specific humanised anti-VEGF monoclonal antibody in patients with previously untreated locally recurrent or MBC, doubling of progression-free survival for all patient subgroups. Bevacizumab is generally well tolerated. The most common adverse events observed in trials hypertension, proteinuria, and wound-healing complications, most of which are grade 1-2 in severity. The registration of bevacizumab for MBC therapy brings new hope for patients. Novel approach of bevacizumab for MBC would be combination chemotherapy and different targeted therapies. Phase III clinical trials of bevacizumab are ongoing in different stages in different settings.

KW - Bevacizumab

KW - Metastatic breast cancer (MBC)

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=55649117367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649117367&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 669

EP - 673

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -